1] Priority Research Centre for Cancer Research, University of Newcastle, Callaghan, NSW, Australia [2] School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
1] Priority Research Centre for Cancer Research, University of Newcastle, Callaghan, NSW, Australia [2] Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Waratah, NSW, Australia.
Oncogene. 2014 May 15;33(20):2577-88. doi: 10.1038/onc.2013.237. Epub 2013 Jun 17.
Increased global protein synthesis and selective translation of mRNAs encoding proteins contributing to malignancy is common in cancer cells. This is often associated with elevated expression of eukaryotic translation initiation factor 4 (eIF4E), the rate-limiting factor of cap-dependent translation initiation. We report here that in human melanoma downregulation of miR-768-3p as a result of activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway has an important role in the upregulation of eIF4E and enhancement in protein synthesis. Melanoma cells displayed increased nascent protein production and elevated eIF4E expression, which was associated with the downregulation of miR-768-3p that was predicted to target the 3'-untranslated region of the eIF4E mRNA. Overexpression of miR-768-3p led to the downregulation of the endogenous eIF4E protein, reduction in nascent protein synthesis and inhibition of cell survival and proliferation. These effects were efficiently reversed when eIF4E was co-overexpressed in melanoma cells. On the other hand, introduction of anti-miR-768-3p into melanocytes upregulated endogenous eIF4E protein expression and increased global protein synthesis. Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that treatment of BRAF(V600E) melanoma cells with the mutant BRAF inhibitor PLX4720 or exposure of either BRAF(V600E) or wild-type BRAF melanoma cells to the MEK inhibitor U0126 resulted in the upregulation of miR-768-3p and inhibition of nascent protein synthesis. This inhibition was partially blocked in cells cointroduced with anti-miR-768-3p. Significantly, miR-768-3p was similarly downregulated, which was inversely associated with the expression levels of eIF4E in fresh melanoma isolates. Taken together, these results identify downregulation of miR-768-3p and subsequent upregulation of eIF4E as an important mechanism in addition to phosphorylation of eIF4E responsible for MEK/ERK-mediated enhancement of protein synthesis in melanoma.
在癌细胞中,普遍存在着增加全球蛋白质合成和选择性翻译编码促进恶性肿瘤的蛋白质的 mRNAs 的现象。这通常与真核翻译起始因子 4(eIF4E)的表达升高有关,eIF4E 是帽依赖性翻译起始的限速因子。我们在这里报告,由于丝裂原活化蛋白激酶激酶(MEK)/细胞外信号调节激酶(ERK)途径的激活,miR-768-3p 的下调在人黑色素瘤中具有重要作用,可上调 eIF4E 并增强蛋白质合成。黑色素瘤细胞显示出新生蛋白质产生增加和 eIF4E 表达升高,这与 miR-768-3p 的下调有关,miR-768-3p 被预测靶向 eIF4E mRNA 的 3'-非翻译区。miR-768-3p 的过表达导致内源性 eIF4E 蛋白的下调,新生蛋白质合成减少,并抑制细胞存活和增殖。当 eIF4E 在黑色素瘤细胞中共同过表达时,这些作用被有效地逆转。另一方面,将抗 miR-768-3p 引入黑素细胞中会上调内源性 eIF4E 蛋白表达并增加整体蛋白质合成。miR-768-3p 的下调似乎是由 MEK/ERK 途径的激活介导的,因为用突变型 BRAF 抑制剂 PLX4720 处理 BRAF(V600E)黑色素瘤细胞或用 MEK 抑制剂 U0126 暴露 BRAF(V600E)或野生型 BRAF 黑色素瘤细胞,会导致 miR-768-3p 的上调和新生蛋白质合成的抑制。这种抑制在共引入抗 miR-768-3p 的细胞中部分被阻断。重要的是,miR-768-3p 也被类似地下调,这与新鲜黑色素瘤分离物中 eIF4E 的表达水平呈负相关。总之,这些结果表明,miR-768-3p 的下调以及随后 eIF4E 的上调是除 eIF4E 磷酸化外,MEK/ERK 介导的黑色素瘤中蛋白质合成增强的另一个重要机制。